- Home
- JBDI vs QNRX Comparison
JBDI vs QNRX Comparison
Compare JBDI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | QNRX |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | Singapore | United States |
| Employees | 104 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 14.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | JBDI | QNRX |
|---|---|---|
| Price | $0.61 | $5.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.8K | ★ 110.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.52 | $5.05 |
| 52 Week High | $2.28 | $41.80 |
Technical Indicators
Market Signals| Indicator | JBDI | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 37.86 |
| Support Level | $0.52 | N/A |
| Resistance Level | $1.09 | $10.42 |
| Average True Range (ATR) | 0.05 | 0.93 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 46.18 | 5.62 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.